2025-07-03 14:07
On July 3, 2025, the TreatGut Pharmaceutical Group–Shandong University Collaboration Series and Microecological Medicine Symposium was held at TreatGut Pharmaceutical Group headquarters.
The event focused on integrating industry, academia, and research in gut microecology and accelerating innovative translation. Academic experts, government representatives, and industry leaders from the Institute of Microbiology of the Chinese Academy of Sciences, Tsinghua University, Shandong University, the Baoshan District Science and Technology Commission, Dachang Town, Nanda Group, and Lingang Nanda witnessed the launch of a jointly established laboratory. Participants discussed clinical applications and the development of microecological medicine, demonstrating a model for deep industry–academia–research collaboration and creating a high-level platform for technological advancement and coordinated development.
Dr. Xiao Chuanxing, Chairman of TreatGut Pharmaceutical Group, and Professor Liu Shuangjiang of Shandong University delivered opening remarks, welcomed the attending experts and scholars, and wished the event every success.
Chairman Xiao described TreatGut's mission to translate microecological innovation into solutions that serve human health and outlined the joint laboratory's role in accelerating the development and application of innovative therapies.
Dr. Xiao Chuanxing, Chairman of TreatGut Pharmaceutical Group
Professor Liu highlighted Shandong University's strong foundation in basic microbiology research and the importance of this university–enterprise partnership in connecting industry, academia, research, and application while integrating original innovation with clinical translation.
Professor Liu Shuangjiang, Shandong University
Together, the speakers presented a vision for using the joint laboratory to address core challenges in microecology and lead industry innovation.
The TreatGut Pharmaceutical Group–Shandong University Joint Gut Microbiota Laboratory was officially unveiled. The partners also launched their first major collaborative project: Preclinical Research and Efficacy Evaluation of Lactobacillus johnsonii.
Joint laboratory unveiling ceremony
Professor Liu Shuangjiang and Dr. Zhang Bangzhou, CEO of TreatGut Intelligent Pharmaceuticals, jointly unveiled the laboratory and introduced its objectives, research plan, and significance for advancing innovative microecological therapies.
Dr. Zhang Bangzhou, CEO of TreatGut Intelligent Pharmaceuticals
Project launch ceremony
Leading scholars from Tsinghua University, Shandong University, and other institutions delivered presentations on frontier research.
Associate Researcher Bi Mingxia of Shandong University presented “Discovery of Novel Probiotics for Neurodegenerative Diseases,” explaining an original therapeutic-development pathway from strain screening to target validation.
Professor Zhu Keke of Tsinghua University presented “Gut Microbiota–Neural–Immune Interactions,” systematically describing new mechanisms through which gut microorganisms regulate neuroimmune networks and proposing an interdisciplinary research framework.
The presentations prompted in-depth discussion of precision microbiota–brain-axis interventions, clinical translation of probiotics, and other emerging topics.
Guests toured TreatGut Pharmaceutical Group's exhibition hall and core R&D and technology platforms, gaining an in-depth view of its full-chain innovation system from strain research to industrial translation.
The symposium created a valuable platform for collaboration across industry, academia, and research in gut microecology. By focusing on gut microbiota–neural–immune interactions, novel probiotic discovery, the launch of the joint laboratory, and its first major project, the event strengthened the exchange of ideas between academia and industry and supported the translation of innovative technologies and the development of precision medicine.
TreatGut Pharmaceutical Group demonstrated its mature microbiota transplantation technology platforms and industrial translation capabilities, while Shandong University contributed its research strength and talent base in microbiology and life sciences. Their Joint Gut Microbiota Laboratory represents a complementary partnership between two strong organizations.
The laboratory will integrate basic research, technology innovation, and industrial translation to establish an efficient industry–academia–research–application model. The partners will address key scientific questions and technical bottlenecks in gut microbiota research, accelerate the delivery of innovation to public health, and contribute TreatGut–Shandong University expertise to the advancement of microecological medicine.
Founded in 2016, TreatGut Pharmaceutical Group is a national high-tech enterprise providing integrated precision microbiota transplantation solutions. The Group integrates R&D, intelligent manufacturing, sales, and services and focuses on human microbiota transplantation across microecological health, diagnostics, therapeutics, drug development, and medical big-data mining.
TreatGut has established six core technology platforms and provides five major solutions built on precision microbiota transplantation. Its seven microecology sectors form a complete closed-loop healthcare system. The Group serves more than 300 medical institutions and has completed over 330,000 microbiota transplantations and gut microbiota tests.
Back to Top
WeChat Official Account
Copyright © TreatGut Pharmaceutical Group. All Rights Reserved. ICP Filing No. 17111070
WeChat Official Account
